These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19801091)

  • 1. Underestimation of the effect of bleeding in clinical trials.
    Stewart RA
    Lancet; 2009 Oct; 374(9696):1145; author reply 1145-6. PubMed ID: 19801091
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban in acute coronary syndromes: too soon to know?
    Gurm HS; Eagle K
    Lancet; 2009 Jul; 374(9683):3-4. PubMed ID: 19539362
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute coronary syndrome and rivaroxaban: not so fast..
    Prescrire Int; 2012 Nov; 21(132):260. PubMed ID: 23210253
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Gómez-Outes A; Suárez-Gea ML; Blázquez-Pérez A; Pozo-Hernández C; Vargas-Castrillón E
    Lancet; 2009 Aug; 374(9691):682; author reply 683. PubMed ID: 19716955
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban in the contemporary treatment of acute coronary syndromes.
    Alexander D; Jeremias A
    Expert Opin Investig Drugs; 2011 Jun; 20(6):849-57. PubMed ID: 21554163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
    Navarese EP; Verdoia M; Schaffer A; Suriano P; Kozinski M; Castriota F; De Servi S; Kubica J; De Luca G
    QJM; 2011 Jul; 104(7):561-9. PubMed ID: 21572108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 10. Delays of event adjudication in the TRITON trial.
    Serebruany VL
    Cardiology; 2010; 115(3):217-20. PubMed ID: 20234133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
    Rodriguez L; Conde D; Lalor N; Elissamburu P; Trivi M
    Am J Emerg Med; 2013 Aug; 31(8):1287. PubMed ID: 23769852
    [No Abstract]   [Full Text] [Related]  

  • 13. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Lazar LD; Lincoff AM
    Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522
    [No Abstract]   [Full Text] [Related]  

  • 17. Review: rivaroxaban causes less fatal bleeding, but does not reduce mortality, compared with VKAs.
    Witt DM
    Ann Intern Med; 2013 Sep; 159(6):JC13. PubMed ID: 24042384
    [No Abstract]   [Full Text] [Related]  

  • 18. Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome.
    De Palma R; James S; Jüni P; Cuisset T
    EuroIntervention; 2014 Jul; 10(3):408-10. PubMed ID: 25042271
    [No Abstract]   [Full Text] [Related]  

  • 19. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of new oral anticoagulants in interventional cardiology].
    Brasselet C; Duval S
    Ann Cardiol Angeiol (Paris); 2012 Dec; 61(6):453-6. PubMed ID: 23102941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.